Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box–Behnken Design Optimization

Background: Ursodeoxycholic acid (UDCA) is a therapeutic agent used for the treatment of cholestatic hepatobiliary diseases in pediatric patients. It is a bile acid that presents high lipophilicity, and it belongs to Class II of the Biopharmaceutical Classification System (BCS), which exhibits low water solubility and high intestinal permeability, which leads to poor oral absorption. The objective of this work was to design and optimize UDCA nanosuspensions by means of the precipitation-ultrasonication method to improve the solubility, dissolution, and oral bioavailability of UDCA. Methods: A three-level, three-factor Box–Behnken design was used to optimize formulation variables and obtain uniform, small-particle-size UDCA nanosuspensions. The independent variables were: stabilizer percentage (X1), amplitude (X2), and sonication time (X3), and the dependent variable was the particle size (Y1). In the precipitation–ultrasonication method, UDCA was dissolved in acetone:PEG 400 (1:1 v/v) and quickly incorporated into the antisolvent (pre-cooled aqueous dispersion of HPMC E-15 0.3%), by means of intense sonication at 50 W for 5 min, controlling temperature through an ice water bath. The lyophilization efficacy was evaluated by means of a cryoprotective efficacy test, working with 10% maltose at −80 °C. The nanosuspensions were characterized by dynamic light scattering (DLS), X-ray diffraction, and scanning electron microscopy (SEM). The physicochemical stability was determined at 25 °C and 4 °C at 7, 14, 30, and 60 days, and the UDCA content was analyzed via HPLC-UV. An in vitro dissolution assay and an oral bioavailability study were performed in male Wistar rats. Results: A significant impact was achieved in the optimized nanosuspension with 0.3% (stabilizer), 50 W (amplitude), and 5 min (sonication time), with a particle size of 352.4 nm, PDI of 0.11, and zeta potential of −4.30 mV. It presented adequate physicochemical stability throughout the study and the UDCA content was between 90% and 110%. In total, 86% of UDCA was dissolved in the in vitro dissolution test. The relative oral bioavailability was similar without significant statistical differences when comparing the lyophilized nanosuspension and the commercial tablet, the latter presenting a more erratic behavior. The pharmacokinetic parameters of the nanosuspension and the commercial tablet were Tmax (1.0 ± 0.9 h vs. 2.0 ± 0.8 h, respectively), Cmax (0.558 ± 0.118 vs. 0.366 ± 0.113 µM, respectively), ΔCmax (0.309 ± 0.099 vs. 0.232 ± 0.056, respectively), AUC (4.326 ± 0.471 vs. 2.188 ± 0.353 µg/mL.h, respectively, p < 0.02), and IAUC0–24h (2.261 ± 0.187 µg/mL.h vs. 1.924 ± 0.440 µg/mL.h, respectively). Conclusions: The developed nanosuspension presents an appropriate dosage and administration for pediatric patients. On the other hand, it exhibits an adequate absorption and UDCA oral bioavailability.

[1]  Yingying Ma,et al.  Nanosuspensions technology as a master key for nature products drug delivery and In vivo fate. , 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  S. Lucangioli,et al.  Dissolution Testing Of Ursodeoxycholic Acid Suspension Using Spe As Sample Preparation , 2022, RPS Pharmacy and Pharmacology Reports.

[3]  N. Jahan,et al.  Formulation and Process Optimization of Rauvolfia serpentina Nanosuspension by HPMC and In Vitro Evaluation of ACE Inhibitory Potential , 2022, Journal of functional biomaterials.

[4]  J. Lulek,et al.  Freeze-drying of drug nanosuspension– study of formulation and processing factors for the optimization and characterization of redispersible cilostazol nanocrystals , 2022, Journal of Drug Delivery Science and Technology.

[5]  I. Song,et al.  Enhancing Dissolution and Oral Bioavailability of Ursodeoxycholic Acid with a Spray-Dried pH-Modified Extended Release Formulation , 2022, Pharmaceutics.

[6]  O. Porwal Box Behnken Design based formulation optimization and characterization of spray dried rutin loaded nanosuspension: State of the art , 2022, South African Journal of Botany.

[7]  M. Ghoneim,et al.  Influence of Stabilizer on the Development of Luteolin Nanosuspension for Cutaneous Delivery: An In Vitro and In Vivo Evaluation , 2021, Pharmaceutics.

[8]  R. Bogner,et al.  Impact of Formulation on the Quality and Stability of Freeze-dried Nanoparticles. , 2021, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  H. Hughes,et al.  Innovative Drying Technologies for Biopharmaceuticals. , 2021, International journal of pharmaceutics.

[10]  P. Coutinho,et al.  Lyoprotective Effects of Mannitol and Lactose Compared to Sucrose and Trehalose: Sildenafil Citrate Liposomes as a Case Study , 2021, Pharmaceutics.

[11]  Ghania Degobert,et al.  Lyophilization of Nanocapsules: Instability Sources, Formulation and Process Parameters , 2021, Pharmaceutics.

[12]  W. Friess,et al.  Freeze-drying of nanoparticles: How to overcome colloidal instability by formulation and process optimization. , 2021, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  K. Ryan,et al.  Production and Isolation of Pharmaceutical Drug Nanoparticles. , 2021, International journal of pharmaceutics.

[14]  E. N. Fissore,et al.  Pharmaceutical suspensions of ursodeoxycholic acid for pediatric patients: in vitro and in vivo studies , 2021, Pharmaceutical development and technology.

[15]  W. Hennink,et al.  Lyophilization stabilizes clinical‐stage core‐crosslinked polymeric micelles to overcome cold chain supply challenges , 2021, Biotechnology journal.

[16]  U. Bolmal,et al.  Exploring the Solvent-Anti-solvent Method of Nanosuspension for Enhanced Oral Bioavailability of Lovastatin. , 2021, Turkish journal of pharmaceutical sciences.

[17]  M. Reibarkh,et al.  Interpreting in vitro Release Performance from Long-Acting Parenteral Nanosuspensions using USP-4 Dissolution and Spectroscopic Techniques. , 2020, Molecular pharmaceutics.

[18]  S. Jacob,et al.  Emerging role of nanosuspensions in drug delivery systems , 2020, Biomaterials Research.

[19]  Vijay Agarwal,et al.  Nanosuspension Technology: Recent Patents on Drug Delivery and their Characterizations , 2019, Recent patents on drug delivery & formulation.

[20]  Rutesh H. Dave,et al.  Development of an amorphous nanosuspension by sonoprecipitation‐formulation and process optimization using design of experiment methodology , 2019, International journal of pharmaceutics.

[21]  B. Gajera,et al.  A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes , 2018, Drug development and industrial pharmacy.

[22]  Rita Ambrus,et al.  Design and characterization of loratadine nanosuspension prepared by ultrasonic‐assisted precipitation , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  Tamizharasi Sengodan,et al.  Augmented anticancer activity of naringenin-loaded TPGS polymeric nanosuspension for drug resistive MCF-7 human breast cancer cells , 2018, Drug development and industrial pharmacy.

[24]  A. Goyal,et al.  Recent Advances in Nanosuspension Technology for Drug Delivery. , 2018, Current pharmaceutical design.

[25]  Flor Sabrina,et al.  LC-MS/MS Method Applied to the Detection and Quantification of Ursodeoxycholic Acid Related Substances in Raw Material and Pharmaceutical Formulation , 2018 .

[26]  A. Barresi,et al.  Use of microreactors and freeze‐drying in the manufacturing process of chitosan coated PCL nanoparticles , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  Dilip Sharma,et al.  Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: Assessment of In‐vitro cytotoxicity , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  Krishna N. Kumar,et al.  Role of freeze-drying in the presence of mannitol on the echogenicity of echogenic liposomes. , 2017, The Journal of the Acoustical Society of America.

[29]  Luyong Zhang,et al.  Quantitative profiling of 19 bile acids in rat plasma, liver, bile and different intestinal section contents to investigate bile acid homeostasis and the application of temporal variation of endogenous bile acids , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  S. Lucangioli,et al.  Development and validation of a LC-UV Method Applied to the Quality Control of Ursodeoxycholic Acid in Raw Material and Pharmaceutical Formulations , 2017 .

[31]  Ye Li,et al.  Preparation and Optimization of Amorphous Ursodeoxycholic Acid Nano-suspensions by Nanoprecipitation based on Acid-base Neutralization for Enhanced Dissolution. , 2017, Current drug delivery.

[32]  A. ElMeshad,et al.  Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box–Behnken Design , 2016, AAPS PharmSciTech.

[33]  Karthik Yadav Janga,et al.  Lipid nanoparticles of zaleplon for improved oral delivery by Box–Behnken design: optimization, in vitro and in vivo evaluation , 2017, Drug development and industrial pharmacy.

[34]  Lulu Wang,et al.  Safety of nanosuspensions in drug delivery. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[35]  J. Feng,et al.  Glabridin nanosuspension for enhanced skin penetration: formulation optimization, in vitro and in vivo evaluation. , 2016, Die Pharmazie.

[36]  Yueqin Ma,et al.  Solidification drug nanosuspensions into nanocrystals by freeze-drying: a case study with ursodeoxycholic acid , 2016, Pharmaceutical development and technology.

[37]  Lulu Wang,et al.  Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies. , 2015, International journal of pharmaceutics.

[38]  Jagannath Sahoo,et al.  Formulation and process optimization of naproxen nanosuspensions stabilized by hydroxy propyl methyl cellulose. , 2015, Carbohydrate polymers.

[39]  Changquan Calvin Sun,et al.  Development of highly stabilized curcumin nanoparticles by flash nanoprecipitation and lyophilization. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[40]  D. Shah,et al.  NANOSUSPENSION TECHNOLOGY: A INNOVATIVE SLANT FOR DRUG DELIVERY SYSTEM AND PERMEABILITY ENHANCER FOR POORLY WATER SOLUBLE DRUGS , 2015 .

[41]  G. Ji,et al.  Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation. , 2014, International journal of pharmaceutics.

[42]  Toi Van Vo,et al.  Amorphous isradipine nanosuspension by the sonoprecipitation method. , 2014, International journal of pharmaceutics.

[43]  Zhenfeng Wu,et al.  A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production – a case study with ursodeoxycholic acid , 2014, Pharmaceutical development and technology.

[44]  S. Lucangioli,et al.  Coenzyme Q in pregnant women and rats with intrahepatic cholestasis , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[45]  Ying Zheng,et al.  Stability of nanosuspensions in drug delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Lishuang Xu,et al.  Preparation, characterization, stability and in vitro-in vivo evaluation of pellet-layered Simvastatin nanosuspensions , 2013, Drug development and industrial pharmacy.

[47]  Karsten Mäder,et al.  Solid lipid nanoparticles , 2012 .

[48]  Wei Wu,et al.  Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. , 2012, International journal of pharmaceutics.

[49]  Y. Liu,et al.  Preparation and Characterization of Ursodeoxycholic Acid Nanosuspension , 2012 .

[50]  Xin Jia,et al.  Box–Behnken experimental design for investigation of microwave-assisted extracted sugar beet pulp pectin , 2012 .

[51]  D. Chiappetta,et al.  Cryoprotection–lyophilization and physical stabilization of rifampicin-loaded flower-like polymeric micelles , 2012, Journal of The Royal Society Interface.

[52]  S. Inghelbrecht,et al.  Freeze drying of nanosuspensions, 2: the role of the critical formulation temperature on stability of drug nanosuspensions and its practical implication on process design. , 2011, Journal of pharmaceutical sciences.

[53]  Jing Ma,et al.  Preparation of a chemically stable quercetin formulation using nanosuspension technology. , 2011, International journal of pharmaceutics.

[54]  R. Tan,et al.  Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying. , 2011, International journal of pharmaceutics.

[55]  S. J. Tsai,et al.  Determination of bile acids in pig liver, pig kidney and bovine liver by gas chromatography-chemical ionization tandem mass spectrometry with total ion chromatograms and extraction ion chromatograms. , 2011, Journal of chromatography. A.

[56]  G. Kulkarni,et al.  Optimization of formulation and process variable of nanosuspension: An industrial perspective. , 2010, International journal of pharmaceutics.

[57]  Jonghwi Lee,et al.  Effective polymeric dispersants for vacuum, convection and freeze drying of drug nanosuspensions. , 2010, International journal of pharmaceutics.

[58]  F. Cui,et al.  Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[59]  R. Gurny,et al.  Investigations on the lyophilisation of MPEG-hexPLA micelle based pharmaceutical formulations. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[60]  Jonghwi Lee,et al.  Cryoprotectants for freeze drying of drug nano-suspensions: effect of freezing rate. , 2009, Journal of pharmaceutical sciences.

[61]  Xiao‐he Xiao,et al.  Process Optimization, Characterization and Pharmacokinetic Evaluation in Rats of Ursodeoxycholic Acid–Phospholipid Complex , 2008, AAPS PharmSciTech.

[62]  A. Fahr,et al.  Stable carbamazepine colloidal systems using the cosolvent technique. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[63]  S. Stainmesse,et al.  Freeze-drying of nanoparticles: formulation, process and storage considerations. , 2006, Advanced drug delivery reviews.

[64]  C. Kuo,et al.  Determination of ursodeoxycholic acid in pharmaceutical preparations by capillary electrophoresis with indirect UV detection. , 2003, Journal of pharmaceutical and biomedical analysis.

[65]  F. Mansour,et al.  Simultaneous Determination of Ursodeoxycholic Acid and Chenodeoxycholic Acid in Pharmaceutical Dosage Form by HPLC-UV Detection. , 2017, Journal of AOAC International.

[66]  J. Emami,et al.  Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design , 2015, Research in pharmaceutical sciences.

[67]  S. Vaghani,et al.  Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation , 2010, Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.

[68]  P. Neuvonen,et al.  High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.